A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

An Open-Label, Multi-Cohort, Multi-center, Non-Randomized, Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04838548
• Other study ID #: MRG003-002
• Status: Recruiting
• Phase: Phase 2
• Start date: September 4, 2020
• Est. completion date: February 2023

Study information

• Verified date: April 2021
• Source: Shanghai Miracogen Inc.
• Contact: Program Director, Master
• Phone: 86-21-61637960
• Email: clinicaltrials[@]miracogen.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: February 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing to sign the ICF and follow the requirements specified in the protocol.
• Age: =18 years,both genders.
• Expected survival time=6 months.
• Patients with histologically confirmed advanced non-small cell lung cancer, and without histologically confirmed small cell lung cancer (SCLC).
• Positive EGFR expression in tumor specimen.
• Failed in the prior second-line or above standard of care therapies.
• Archival or biopsy tumor specimens should be provided.
• Patients must have measurable lesions according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).
• ECOG performance score 0 or 1.
• AEs related to prior systemic chemotherapy and radical/extensive radiotherapy have recovered to = Grade 1 based on National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE V5.0).
• No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) = 50%.
• Organ functions and coagulation function must meet the basic requirements.
• Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.

Exclusion Criteria:

• History of hypersensitivity to any component of the investigational product.
• No documented progression after prior treatment, or recurrence during or after prior treatment.
• Received radiotherapy, chemotherapy, biologicals, immunotherapy or other anti-tumor drugs within 4 weeks prior to the first dose of study treatment.
• Presence of central nervous system metastasis.
• Patients with significant clinical symptoms such as pleural, abdominal or pericardial effusion requiring puncture drainage prior to the first dose of study drug.
• Any severe or uncontrolled systemic disease judged by the investigator.
• Patients with poorly controlled heart diseases.
• Evidence of active infections, including Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV) infection.
• Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic therapy.
• Prior history of other primary malignancies.
• History of the following ophthalmologic abnormalities: severve dry eye syndrome; keratoconjunctivitis sicca; severe exposure keratitis; any other condition that may increase the risk of corneal epithelial damage.
• History of severe skin disease requiring interruption of previous EGFR targeted therapy; or chronic skin disease requiring oral or intravenous therapy.
• History of interstitial lung disease (ILD) or pneumonitis, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.
• Pulmonary radiotherapy > 30 Gy within 6 months prior to first dose of study drug.
• Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
• Patients with active autoimmune disease or history of autoimmune disease, who are using immunosuppressive agents or systemic hormone therapy and still receiving within 2 weeks prior to enrollment.
• History of allogeneic tissue or solid organ transplant.
• Female patients with a positive serum pregnancy test or who are breast feeding or do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment.
• Active uncontrolled concomitant diseases that might limit patient's compliance with study requirements, or compromise patient's ability to provide written informed consent.
• Other conditions inappropriate for participation in this clinical trial, at the discretion of the investigator.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• MRG003
Administered intravenously

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Miracogen Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR) by Investigator	ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.	Baseline to study completion, up to 12 months
Secondary	Progression Free Survival (PFS)	PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.	Baseline to study completion, up to 12 months
Secondary	Duration of Response (DoR)	DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.	Baseline to study completion, up to 12 months
Secondary	Time to Response (TTR)	TTR is defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation.	Baseline to study completion, up to 12 months
Secondary	Disease Control Rate (DCR)	DCR is defined as the proportions of patients achieving CR, PR, and stable disease (SD) after treatment.	Baseline to study completion, up to 12 months
Secondary	Overall Survival (OS)	OS is defined as the duration from the start of treatment to death of any cause.	Baseline to study completion, up to 12 months
Secondary	Adverse Events (AEs)	Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.	Baseline to 60 days after the last dose of study treatment